- Home
- STBA vs ARVN Comparison
STBA vs ARVN Comparison
Compare STBA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STBA
- ARVN
- Stock Information
- Founded
- STBA 1902
- ARVN 2015
- Country
- STBA United States
- ARVN United States
- Employees
- STBA N/A
- ARVN N/A
- Industry
- STBA Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- STBA Finance
- ARVN Health Care
- Exchange
- STBA Nasdaq
- ARVN Nasdaq
- Market Cap
- STBA 1.6B
- ARVN 1.8B
- IPO Year
- STBA N/A
- ARVN 2018
- Fundamental
- Price
- STBA $41.80
- ARVN $18.97
- Analyst Decision
- STBA Hold
- ARVN Strong Buy
- Analyst Count
- STBA 1
- ARVN 13
- Target Price
- STBA $41.00
- ARVN $63.00
- AVG Volume (30 Days)
- STBA 137.3K
- ARVN 855.2K
- Earning Date
- STBA 01-23-2025
- ARVN 10-30-2024
- Dividend Yield
- STBA 3.17%
- ARVN N/A
- EPS Growth
- STBA N/A
- ARVN N/A
- EPS
- STBA 3.51
- ARVN N/A
- Revenue
- STBA $386,292,000.00
- ARVN $161,100,000.00
- Revenue This Year
- STBA N/A
- ARVN $237.44
- Revenue Next Year
- STBA $1.76
- ARVN N/A
- P/E Ratio
- STBA $12.22
- ARVN N/A
- Revenue Growth
- STBA N/A
- ARVN 1.07
- 52 Week Low
- STBA $28.83
- ARVN $18.51
- 52 Week High
- STBA $45.79
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- STBA 47.83
- ARVN 31.95
- Support Level
- STBA $41.65
- ARVN $18.51
- Resistance Level
- STBA $43.00
- ARVN $19.90
- Average True Range (ATR)
- STBA 0.93
- ARVN 1.55
- MACD
- STBA -0.20
- ARVN -0.64
- Stochastic Oscillator
- STBA 19.12
- ARVN 5.65
About STBA S&T Bancorp Inc.
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. It has one reporting unit, Community Banking. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.